Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS

Louise de Swart, Alex Smith, Detlef Haase, Pierre Fenaux, Argiris Symeonidis, Jaroslav Cermak, Guillermo Sanz, Reinhard Stauder, Moshe Mittelman, Eva Hellström-Lindberg, Luca Malcovati, Saskia Langemeijer, Mette Skov-Holm, Krzysztof Mądry, Ulrich Germing, Antonio Medina Almeida, Aurelia Tatic, Aleksandar Savic, Njetočka Gredelj Šimec, Corine van MarrewijkAgnes Guerci-Bresler, Laurence Sanhes, Elisa Luño, Dominic Culligan, Odile Beyne-Rauzy, Sonja Burgstaller, Nicole Blijlevens, David Bowen, Theo de Witte

Research output: Contribution to journalArticle

Abstract

Conventional karyotype is one of the most relevant prognostic factors in MDS. However, about 50% of patients with MDS have a normal karyotype. Usually, 20–25 normal metaphases (nMP) are considered to be optimal to exclude small abnormal clones which might be associated with poor prognosis. This study evaluated the impact of examining a suboptimal number of metaphases in patients recruited to the EUMDS Registry with low and intermediate-1 risk according to IPSS. Only 179/1049 (17%) of patients with a normal karyotype had a suboptimal number of nMP, defined as less than 20 metaphases analyzed. The outcome (overall survival and progression-free survival) of patients with suboptimal nMP was not inferior to those with higher numbers of analyzed MP both in univariate and multivariate analyses. For patients with an abnormal karyotype, 224/649 (35%) had a suboptimal number of MP assessed, but this did not impact on outcome. For patients with a normal karyotype and suboptimal numbers of analyzable metaphases standard evaluation might be acceptable for general practice, but we recommend additional FISH-analyses or molecular techniques, especially in candidates for intensive interventions.

Original languageEnglish
Pages (from-to)21-26
Number of pages6
JournalLeukemia Research
Volume67
DOIs
Publication statusPublished - Apr 1 2018

Keywords

  • Cytogenetics
  • Karyotype
  • Lower-risk
  • Metaphases
  • Myelodysplastic syndromes
  • Overall survival
  • Progression-free survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS'. Together they form a unique fingerprint.

  • Cite this

    de Swart, L., Smith, A., Haase, D., Fenaux, P., Symeonidis, A., Cermak, J., Sanz, G., Stauder, R., Mittelman, M., Hellström-Lindberg, E., Malcovati, L., Langemeijer, S., Skov-Holm, M., Mądry, K., Germing, U., Almeida, A. M., Tatic, A., Savic, A., Šimec, N. G., ... de Witte, T. (2018). Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. Leukemia Research, 67, 21-26. https://doi.org/10.1016/j.leukres.2018.01.022